Disposition of 3338 shares by Sing George L of Regeneron Pharmaceuticals at 413.33 subject to Rule 16b-3

REGN Stock  USD 718.15  2.96  0.41%   
About 56% of Regeneron Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Regeneron Pharmaceuticals suggests that many traders are alarmed. Regeneron Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Regeneron Pharmaceuticals. Many technical investors use Regeneron Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Regeneron Pharmaceuticals Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at bizjournals.com
bizjournals News
  
Disposition of 3338 non-qualified stock option (right to buy) at 413.33 of Regeneron Pharmaceuticals by Sing George L on 31st of December 2024. This event was filed by Regeneron Pharmaceuticals with SEC on 2024-12-31. Statement of changes in beneficial ownership - SEC Form 4

Regeneron Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Regeneron Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Regeneron Pharmaceuticals Fundamental Analysis

We analyze Regeneron Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regeneron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regeneron Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Liabilities

Current Liabilities Comparative Analysis

Regeneron Pharmaceuticals is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Regeneron Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Regeneron Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Regeneron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Regeneron Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Regeneron Pharmaceuticals Related Equities

MDGLMadrigal Pharmaceuticals   1.88   
0%
100.0%
SRPTSarepta Therapeutics   1.77   
0%
94.0%
PTCTPTC Therapeutics   1.44   
0%
76.0%
KRYSKrystal Biotech   1.17   
0%
62.0%
APLSApellis Pharmaceuticals   0.90   
0%
47.0%
RAREUltragenyx   0.85   
0%
45.0%
ARWRArrowhead Pharmaceuticals   0.71   
0%
37.0%
BMRNBiomarin Pharmaceutical   0.51   
0%
27.0%
BGNEBeiGene   0.39   
0%
20.0%
IONSIonis Pharmaceuticals   0.35   
0%
18.0%
ALNYAlnylam Pharmaceuticals   0.28   
0%
14.0%
NVONovo Nordisk   0.15   
0%
7.0%
INCYIncyte   0.14   
0%
7.0%
NTLAIntellia Therapeutics   0.74   
39.0%
0%
CRSPCrispr Therapeutics   0.99   
52.0%
0%
UTHRUnited Therapeutics   1.08   
57.0%
0%
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.298
Earnings Share
40.43
Revenue Per Share
128.691
Quarterly Revenue Growth
0.106
Return On Assets
0.0741
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.